Cardax Inc (CDXI)
Cardax, Inc. is a healthcare company quoted on OTC Markets under the symbol CDXI. The company focuses on biopharmaceutical development and the commercialization of products aimed at inflammatory health and chronic conditions associated with inflammation and oxidative stress. Its marketed product, ZanthoSyn, is a dietary supplement containing astaxanthin designed for health and longevity, and it is sold primarily through e-commerce and wholesale channels. Cardax is also advancing CDX-101, an astaxanthin-based pharmaceutical candidate being developed for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia, as well as CDX-301, a zeaxanthin candidate under development for macular degeneration. The company is based in Honolulu, Hawaii.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CDXI
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
0 K
|
—
|
—
|
—
|
—
|
—
|
—
|